BridgeBio Pharma, Inc. (BBIO) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Is BridgeBio Pharma, Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, BridgeBio Pharma, Inc. (BBIO) trades at $74.03 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: BridgeBio Pharma, Inc.
Market cap $14B · 52 weeks $61 – $90 (17 % below the high) · P/E no earnings · Dividend none · Next earnings February 23, 2027 · expected EPS -$0.53 · Closing price, Nov 3 · accounts published Oct 29.
- Valuation: P/Sales 16.5× (no earnings).
- Balance sheet: Altman Z −3.6 (fragile).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 0 of 4 pass
- Cash Runway 16 months, fails.
- Total Debt 4.7×, fails.
- R&D / Market cap 3.3 %, fails.
- Market cap / Cash 24.9×, fails.
- Annual cash burn $2.26, info.
Against its peers (reference peers) — BridgeBio Pharma, Inc.: P/E —; EV/EBITDA —; ROIC -23.6 %; $14.4B. Ascendis Pharma A/S (P/E 18.5×; EV/EBITDA 183×; ROIC 5.8 %; $16.5B), BioMarin Pharmaceutical Inc. (P/E —; EV/EBITDA 31.9×; ROIC -1.0 %; $10.8B), Alnylam Pharmaceuticals, Inc. (P/E 8.1×; EV/EBITDA 16.6×; ROIC 15.4 %; $21.4B).
Profitability
| Return on Equity | 26.76% |
| Return on Invested Capital | -23.63% |
| Return on Assets | -26.38% |
| Gross Margin | 93.51% |
| Operating Margin | -43.35% |
| Net Margin | -60.30% |
Financial Health
| Debt / Equity | -1.50 |
| Current Ratio | 2.09 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.58 |
Price Performance
| 1 month | +13.40% |
| 3 months | -9.42% |
| Year-to-date | -1.95% |
| 1 year | +22.21% |
| 3 years | +160.15% |
| 5 years | +40.42% |
Related companies: ALNY · ASND · IONS · BMRN · SRRK · PTCT · DNLI · TVTX
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks